Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK health collaboration to tackle infection

This article was originally published in Scrip

Executive Summary

The UK Clinical Research Collaborationhas pledged £9 million to fund the establishment of two infection research consortia in London and Oxford, to further collaborative research into the areas of hospital-acquired infections and antibiotic resistance. The Oxford consortium will focus on research on disease transmission with the aim of controlling their spread, using DNA sequencing techniques to speed up classifying and identifying them. This should make it easier to deal with local infection outbreaks, identify particularly virulent strains and help improve infection control guidelines, the UKCRC says. The London consortium, based at Imperial College London, will conduct research into individual and organisational behavioural change, modelling, epidemiology, rapid diagnosis and surveillance of selected infectious diseases to address and prevent healthcare-associated infection. Infections the consortia hope to tackle include tuberculosis, MRSA and Clostridium difficile. A second round of funding under the initiative is scheduled for late 2009.

You may also be interested in...

Botox shows hope in chronic migraine

Cerimon receives positive Phase II data on diclofenac patch

Cerimon Pharmaceuticals' once-daily topical-patch formulation of the NSAID diclofenac gave significantly better average pain relief than placebo in ankle-sprain patients who carried out their daily activities in a Phase II trial, at the third day in the study.

Lilly's Alimta among SMC's September recommendations

Following a second resubmission, the Scottish Medicines Consortiumhas accepted Lilly's Alimta (pemetrexed) for restricted use within the Scottish NHS as a monotherapy for the second-line treatment of locally advanced or metastatic non-small cell lung cancer.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts